ENTA has very low market cap, and very rich pipeline in very hot areas. The analyst thinks because Abive is buying Shire they will not buy ENTA any more. Wrong, ENTA will be a small acquisition even at 100% premium. If economically makes sense , then Abive will buy, and it sure does make sense for Avive to buy this incredible value Biotech.
Surely they would not owned that many share if conclusion such as contributor to SA could be reached with publicly available data could be reached, Fidelity would not have this many shares.
Isis Pharmaceuticals Inc. (ISIS), a maker of gene therapy treatments, may seek to expand use of an experimental drug targeting triglycerides to fight heart disease, a move an analyst says could add $2 billion in sales.
The drug targets the APOC3 gene and is now aimed solely at a rare disease that’s linked to diabetes and pancreatitis and affects about 5,000 people. Two studies this week, however, have also tied the gene to lower risk of heart disease, an illness that kills 600,000 people yearly, a much larger target.
The research, done independently of Isis, was highlighted in the New England Journal of Medicine. It may open a new window of opportunity for Isis once the drug, called ISIS-APOCIIIRx and heading to final testing, is approved and may spark interest from potential acquirers, analysts said.
“We’re weighing how we want to take full advantage of this breakthrough, and as we do that we have to consider the potential broader development of the follow on product,” Isis Chief Executive Officer Stanley Crooke said by telephone. “We have a great deal of licensing interest for this drug.”
In the New England Journal of Medicine studies, mutations in the APOC3 gene decreased the risk of a heart attack by about 40 percent. Adding value to the current drug could open the company up to a takeover bid, said Joshua Schimmer, a Piper Jaffray & Co. analyst in New York.
The Carlsbad, California-based company has “a super deep pipeline, and none of it is adequately reflected in the stock price,” Schimmer said in a telephone interview. “At this valuation, it would be ripe for a hostile event.”
Isis, founded by by Crooke in 1989, has grown to a $4.09 billion market capitalization and a pipeline of 32 products. Today the stock rose 3.2 percent to $34.82 at 4 p.m. New York time. It has dropped 41 percent since reaching a record high of $59 on February 21, compared with a 6.8 percent drop
Are you stupid or what, you call under $300 million market cap, massive? Maybe you don't know what market cap means. didn't one biotech with no revenue just got bought out for $3.8 Billion?
This despite the fact that ENTA's drug is rear approval, and IDIX is in 2nd inning on their drug.
not $2.5 billion, $3.8 Billion, ENTA has a drug in verge of approval, and same valuation as IDIX will put ENTA at $200
This management is a bad news, they keep falling short. They buy the leftover and depleted wells, brag about how they are quadrupling the reserves, but it is all talk and a management scam, they deliver #$%$, over and over.
The enterprise value of Mankind is $2.7 at today's price and $3.1 at when price was $8.29, not $5 Billion he has at his Twitter. The total market for Nordisk and Pfizer is $3.71 Billion and not $3 Billion as he claims. This guy is dishonest, and he must be a paid basher, why else would he lie any chance he gets.
A 25% capture of the market share as she is expected to do,will give Mankind $750 million sales, a 6 times sales multiple should give MNKD a market cap of $4.5 Billion, which translates into $12.60 price. If the Afreeza expands the market, or captures larger share of the market, stock will be even higher. Capturing 25% is what is being talked about.
I read it on SA without mentioning the source, where is the link to NY Times?, or a link the attributes it to NY Times?
Apparently this problem with undisclosed promotions is so widespread that SEC has investigate just about every small cap company. I think this might work to CYTR's benefit as SEC may go after promoters, and be too diluted to go after so many companies. But lets face it why are so many stupid people making so many stupid mistake. This company has a great drug, they did not have to do this, they should fire their investor relation, and their legal guys.
Moron, how could it be a pump and dump? they have not announced any news, who is pumping? You must be one of those minimum wage bashers behind the computer whole day, trying to make ends meet dishonestly.
CYTR drug if successful, and there is plenty of test data from PII to suggest that works will propel this stock to over $100. But meanwhile it looks like they have done something very stupid on promoting the stock before the secondary offering they did, now what. Let things roll along, the Vulture attorneys with class action law suits and anything else that comes along their way. Before the law suits and any investigation, if any comes close to being finalized, the PIII results will drive this stock well over $30. They can then settle with investors that bought it's shares at $7 still come out ahead. Consider the shares as a loan and penalties as a interest on loan. Court will be a lot more lenient toward a mistake that was made to bring a life saving drug to the market against GALE which was done for enriching insiders.
what did I tell you? The price is way below where it should be, watch short covering develop. Look at Yahoo under insider actions, all buys, this is not GALE